These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24192755)

  • 1. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform.
    Spiros A; Roberts P; Geerts H
    J Parkinsons Dis; 2013; 3(4):569-80. PubMed ID: 24192755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference.
    Rakshit H; Chatterjee P; Roy D
    Biochem Biophys Res Commun; 2015 Feb; 457(3):280-7. PubMed ID: 25576361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological treatment of parkinsonian tremor].
    Yokochi F
    Nihon Rinsho; 2000 Oct; 58(10):2091-5. PubMed ID: 11068452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone improves motor function in Parkinson's disease.
    Mitchell E; Thomas D; Burnet R
    J Clin Neurosci; 2006 Jan; 13(1):133-6. PubMed ID: 16410216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings.
    Spieker S; Löschmann P; Jentgens C; Boose A; Klockgether T; Dichgans J
    Clin Neuropharmacol; 1995 Jun; 18(3):266-72. PubMed ID: 8635185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
    Tarsy D; Scollins L; Corapi K; O'Herron S; Apetauerova D; Norregaard T
    Stereotact Funct Neurosurg; 2005; 83(5-6):222-7. PubMed ID: 16534254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary chin tremor in Parkinson's disease.
    Erer S; Jankovic J
    Clin Neurol Neurosurg; 2007 Nov; 109(9):784-5. PubMed ID: 17618046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budipine in Parkinson's tremor.
    Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):53-5. PubMed ID: 16784759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
    Cichonska A; Rousu J; Aittokallio T
    Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral caudal zona incerta deep brain stimulation for Parkinsonian tremor.
    Blomstedt P; Fytagoridis A; Åström M; Linder J; Forsgren L; Hariz MI
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1062-6. PubMed ID: 22709794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative re-organization mechanism for reducing tremor in Parkinson's disease patients.
    Schalow G; Pääsuke M; Jaigma P
    Electromyogr Clin Neurophysiol; 2005 Dec; 45(7-8):407-15. PubMed ID: 16438348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy.
    Binder S; Deuschl G; Volkmann J
    Eur Neurol; 2009; 61(3):149-53. PubMed ID: 19092251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.
    Roberts P; Spiros A; Geerts H
    Front Pharmacol; 2016; 7():6. PubMed ID: 26869923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease.
    Rana AQ; Vaid HM; Edun A; Dogu O; Rana MA
    J Neurol Sci; 2012 Dec; 323(1-2):158-61. PubMed ID: 23062324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.